Monika Sosnowska

European medtech companies navigate complex real estate decisions across innovation clusters, balancing flexibility needs with regulatory requirements.

Life sciences real estate is a specialised segment expanding at a speed that outpaces most traditional property sectors.

Life science contract organisations balance real estate ownership (73 per cent) vs leasing (27 per cent) based on financial, operational, and strategic considerations.

Pharmaceutical giants are transforming their real estate strategies. Industry leaders are shifting from traditional property ownership to strategic lease-ownership balancing for financial efficiency and flexibility.

As AI reshapes both biotech and cloud computing, investors are increasingly drawn to these surprisingly similar asset classes.